(secondQuint)Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment.

 pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment.

 AUC0-t, AUC0 inf, Cmax, Tmax, z, t1/2, MRTinf, CL, CLnr, Vss, Vz.

 Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment@highlight

The purpose of this study is to evaluate the pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment.

